for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Briacell Therapeutics Corp

BCTX.OQ

Latest Trade

7.86USD

Change

0.30(+3.97%)

Volume

158,512

Today's Range

7.22

 - 

7.86

52 Week Range

2.82

 - 

8.88

As of on the TSX Venture Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
7.56
Open
7.54
Volume
158,512
3M AVG Volume
0.23
Today's High
7.86
Today's Low
7.22
52 Week High
8.88
52 Week Low
2.82
Shares Out (MIL)
15.27
Market Cap (MIL)
150.86
Forward P/E
--
Dividend (Yield %)
--

Next Event

Briacell Therapeutics Corp at Benzinga Healthcare Small Cap Conference (Virtual)

Latest Developments

More

Briacell And Imaginab Announce Collaboration To Evaluate Immunotherapy Imaging Technology In Advanced Breast Cancer

Briacell Therapeutics Says Will Voluntarily Delist Its Common Shares From Trading On Frankfurt Stock Exchange Effective August 19

Ault Global Holdings Inc Reports 6.15% Stake In Briacell Therapeutics Corp As Of August 6

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Briacell Therapeutics Corp

BriaCell Therapeutics Corp. is a Canada-based immuno-oncology focused biotechnology company developing targeted approaches for the management of cancer. The Company, in collaboration with Incyte Corporation, is conducting a Phase I/IIa clinical trial of Bria-IMT in combination with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and manufacturing logistics associated with other personalized immunotherapies.

Industry

Biotechnology & Drugs

Contact Info

235-15th Street

WEST VANCOUVER, BC

V7T 2X1

Canada

+1.604.9211810

http://www.briacell.com/

Executive Leadership

Jamieson Bondarenko

Chairman of the Board

William V. Williams

President, Chief Executive Officer, Director

Gadi Levin

Chief Financial Officer, Corporate Secretary

Marc Lustig

Director

Vaughn C. Embro-Pantalony

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.39
Price To Cash Flow (TTM)
70.52
Total Debt To Equity (MRQ)
1.12
LT Debt To Equity (MRQ)
1.12
Return on Investment (TTM)
19.45
Return on Equity (TTM)
16.03

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up